Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
GermanyIPO:
12 December 2018Website:
http://www.immatics.comNext earnings report:
21 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 21:37:48 GMTDividend
Analysts recommendations
Institutional Ownership
IMTX Latest News
Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Immatics (IMTX) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.35 per share a year ago.
Immatics (IMTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Immatics is an early-stage biotech focused on cell-based immunotherapies for solid cancers. Their ACTEngine pipeline shows promise, particularly IMA203/IMA203CD8 targeting the PRAME antigen. Valuation estimates suggest a potential stock price of ~$19.26 based on conservative revenue assumptions.
H ouston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of its previously announced underwritten public offering of 16,250,000 ordinary shares at a public offering price of $9.25 per share. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be approximately $150 million. The offering is expected to close on October 15, 2024, subject to customary closing conditions. In addition, Immatics has granted the underwriters a 30-day option to purchase up to 2,437,500 additional shares at the public offering price, less the underwriting discount.
On Thursday, Immatics N.V. IMTX stock is trading lower after the company commenced an underwritten public offering of $150 million.
Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the commencement of an underwritten public offering of its ordinary shares. The offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST
Houston, Texas and Tuebingen, Germany, October 4, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming oral and poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer in Houston, Texas from November 6 - 10, 2024.
Houston, Texas and Tuebingen, Germany, September 16, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today presented the proof-of-concept clinical data for the first candidate of its next-generation, half-life extended TCR Bispecifics platform, TCER® IMA401 (MAGEA4/8), during an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024.
- 1(current)
What type of business is Immatics NV?
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
What sector is Immatics NV in?
Immatics NV is in the Healthcare sector
What industry is Immatics NV in?
Immatics NV is in the Biotechnology industry
What country is Immatics NV from?
Immatics NV is headquartered in Germany
When did Immatics NV go public?
Immatics NV initial public offering (IPO) was on 12 December 2018
What is Immatics NV website?
https://www.immatics.com
Is Immatics NV in the S&P 500?
No, Immatics NV is not included in the S&P 500 index
Is Immatics NV in the NASDAQ 100?
No, Immatics NV is not included in the NASDAQ 100 index
Is Immatics NV in the Dow Jones?
No, Immatics NV is not included in the Dow Jones index
When was Immatics NV the previous earnings report?
No data
When does Immatics NV earnings report?
The next expected earnings date for Immatics NV is 21 November 2024